Download Files:
Eltrombopag (Olamine)
$73 – $294
Products Details
Product Description
– Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
Web ID
– HY-15306A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C29H36N6O6
Citations
– Eur J Clin Pharmacol. 2022 Aug 3.|Front Pharmacol. 2020 Nov 16;11:582625.|Blood Adv. 2017 Feb 28;1(7):468-476.|BMC Cancer. 2020 Nov 30;20(1):1171.|Cells. 2022, 11(3), 319.|Curr Microbiol. 2021 Feb 21.|J Pharm Biomed Anal. 235, 25 October 2023, 115683|J Thromb Haemost. 2022 May 27.|Virology. 2023 Jun 21.|Viruses. 2019 Apr 25;11(4):385.
References
– [1]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.|[2]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372.|[3]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.|[4]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702.|[5]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.
CAS Number
– 496775-62-3
Molecular Weight
– 564.63
Compound Purity
– 99.96
SMILES
– O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O.NCCO.NCCO
Clinical Information
– Launched
Research Area
– Cancer; Infection; Cardiovascular Disease
Solubility
– DMSO : ≥ 50 mg/mL
Target
– Apoptosis;Bacterial;Thrombopoietin Receptor
Pathway
– Anti-infection;Apoptosis;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
